According to the Company's Articles of Association, the Board of Directors shall consist of a minimum of three and a maximum of seven Board members without deputy directors. The Company's Board of Directors currently consists of five board members without deputy directors. The Board members are elected for the period until the end of the Annual General Meeting of 2021.
Board member and Chairman of the Board since 2016.
Education and experience: Bachelor of Science in medical microbiology from the University of Manchester and Master of Science in Management and Economics from the University of London, as well as a Fellow from the London Business School Sloan Program. Simon Cartmell has over 40 years of experience in senior executive and board positions in both private and listed companies in the pharmaceutical, biotech, medtech and diagnostic sectors.
Other current roles: Board positions at Oviva AG, Axis Spine Technology Ltd., Route2Advisors Ltd. and Route2Property Ltd.
Holdings in OssDsign: 45 000 shares and 122 332 subscription options.
Simon Cartmell is independent in relation to the Company, the Company management and the Company's major shareholders.
Board member since 2019..
Education and experience: Master of Science in Chemical Engineering (with specialization in biochemistry), Royal Institute of Technology, Stockholm. Anders Qvarnström has 34 years international experience from several general management positions in listed and private biotech and medtech companies. He has experience in running a global business and in setting up and running sales and marketing in EU, Japan and the US. He has recently been Country Manager for Nilfisk Inc. Japan, Divisional Manager at St. Jude Medical Japan Co. as well as COO for Global Kinetics Corp. (Australia).
Other current roles: -
Holdings in OssDsign: 23 000 shares and 30 583 subscription options.
Anders Qvarnström is independent in relation to the Company and company management and in relation to the Company's major shareholders.
Board member since 2016.
Education and experience: Certified civil engineer in material science, senior lecturer in material science and professor in applied material science at Uppsala University. Håkan Engqvist has lengthy research experience with focus on bioceramic materials as a replacement for hard tissue as well as on systems for pharmaceutical distribution. Engqvist is the primary inventor of the company’s product OssDsign Cranial as well as co-founder of OssDsign and has also founded several other companies. Engqvist also has experience from board positions in a number of companies, including pharmaceutical companies and medtech.
Other current roles: Board member and CEO of Aduro Material AB. Chairman of the board at Psilox AB. Board member at Emplicure AB. Partner of GP Bio Ltd.
Holdings in OssDsign: 224 000 shares and 122 332 subscription options.
Håkan Engqvist is independent in relation to the Company and company management and in relation to the Company's major shareholders.
Board member since 2019.
Education and experience: Bachelor of Science in Chemistry from McGill University in 1986 as well as a Master of Business Administration (MBA) from JL Kellogg Graduate School of Management, Northwestern University in 1992. Newton Aguiar has considerable experience of board work and has been a board member of a number of public and private companies, including healthcare companies based in Sweden. He has also been Senior Healthcare Advisor in Warburg Pincus as well as partner and Head of Europe for Avista Capital.
Other current roles: Board member of Intervacc AB and Palette Life Sciences AB.
Holdings in OssDsign: 41 600 shares and 30 583 subscription options.
Newton Aguiar is independent in relation to the Company and company management and in relation to the Company's major shareholders.
Board member since 2015.
Education and experience: MD, PhD, Assoc Prof in Cardiology at Karolinska Institute. Viktor Drvota has over 17 years’ experience from venture capital in life sciences. Drvota was responsible for life science at SEB Venture Capital 2002–2016 and has many years of experience of board duties in biotech and medtech companies
Other current roles: CEO of Karolinska Development AB. Chairman of the board at Modus Therapeutics AB, Modus Therapeutics Holding AB, Umecrine Cognition AB and KDev Investments AB. Board member at UC Research AB, Dilafor AB and Dilafor Incentive AB. Deputy board member at Promimic AB and Svenska Vaccinfabriken Produktion AB.
Holdings in OssDsign: -
Viktor Drvota is independent in relation to the Company and company management and in relation to the Company's major shareholders.